"Food noise" is colloquial term describing constant mental preoccupation with food experienced by many individuals with obesity, characterized by: Cognitive Symptoms : Persistent thoughts about food throughout day Planning next meal while eating current meal Difficulty concentrating on non-food activities due to food thoughts Mental exhaustion from constantly resisting food urges Sensation of being controlled by food rather than controlling eating Emotional Symptoms : Guilt and shame about food preoccupation Frustration with inability to "just stop thinking about food" Mood impacts when unable to satisfy cravings Social impacts (preoccupation during meetings, conversations, activities) Behavioral Symptoms : Frequent trips to kitchen or food locations Eating when not physically hungry Difficulty adhering to meal plans despite intention Secretive eating or hiding food Eating rapidly or mindlessly Neurological Basis : According to neuroscience research: Food preoccupation involves dysregulation of reward pathways (mesolimbic dopamine system) Obesity associated with altered brain responses to food cues Brain scans show heightened activation in reward centers when viewing food images Reduced activation in satiety/inhibition centers Not simply "lack of willpower"-represents actual neurological differences How GLP-1 Medications Reduce Food Noise : According to research and patient reports: GLP-1 receptors located in brain regions controlling reward and satiety Medication appears to normalize appetite signaling Reduces intensity and frequency of food thoughts Decreases urgency of cravings Improves ability to make conscious food choices rather than reactive eating Member-Reported Food Noise Experiences : According to patient testimonials published across telehealth platforms (not specific to Ro): Common Descriptions : "The constant background noise about food just
Some patients notice appetite changes within the first few weeks of treatment
There are no known drug interactions between Ozempic and any antidepressants (including both the injectable and not-yet-released oral versions of Ozempic)
Abstract: Brown, K., DeCoffe, D., Molcan, E., & Gibson, D
PMCID: PMC4075452 Griffith O, Meister A (1979) Potent and specific inhibition of glutathione synthesis by buthionine sulfoximine (S-n-butyl homocysteine sulfoximine)
A1C reduction with Rybelsus (oral semaglutide) In one clinical study, people taking oral semaglutide daily lowered their A1C (a blood sugar test) by 1.2% over 26 weeks
